YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin
Authors:
- 3 March 2021
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 44 (3) , 689-699
Abstract
Background Sorafenib is the standard first-line treatment for advanced hepatocellular carcinoma (HCC), but its use is hampered by secondary drug resistance. Yes-associated protein (YAP) is a downstream effector of the Hippo signaling pathway, which is crucial for liver tumorigenesis. As yet, however, the mechanism underlying sorafenib resistance and the role of YAP therein is not fully understood and needs to be explored further. Methods Western blotting, flow cytometry and CCK-8 assays were used to assess the role of YAP in HCC sorafenib resistance. Next, qRT-PCR and Western blotting were performed to identify survivin as a YAP downstream effector, and rescue experiments were performed to confirm that YAP induces sorafenib resistance via survivin. Additionally, Western blotting, flow cytometry and in vivo xenograft models were used to evaluate the effect of verteporfin in combination with sorafenib on HCC. Results We found that sorafenib enhances YAP nuclear accumulation and activation, thereby promoting sorafenib resistance through inhibiting apoptosis in HCC cells. In addition, we found that survivin acts as a downstream mediator of YAP to resist sorafenib-induced apoptosis. Pharmacological inhibition of YAP by verteporfin increased the sensitivity of HCC cells to sorafenib and reversed sorafenib resistance. Moreover, verteporfin in combination with sorafenib significantly suppressed in vivo HCC tumor growth. Conclusions Our data indicate that YAP promotes sorafenib resistance through upregulation of survivin expression in HCC cells. Targeting YAP may be a therapeutic strategy to improve the antitumor effects of sorafenib in HCC.Keywords
Funding Information
- National Natural Science Foundation of China (81874188)
- National Natural Science Foundation of China (31501123)
This publication has 44 references indexed in Scilit:
- Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinomaWorld Journal of Hepatology, 2013
- Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAPGenes & Development, 2012
- The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewalNature Cell Biology, 2011
- Hippo Pathway Effector Yap Is an Ovarian Cancer OncogeneCancer Research, 2010
- The Hippo Signaling Pathway in Development and CancerDevelopmental Cell, 2010
- The evasive promise of antiangiogenic therapyJournal of Hepatology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Transforming properties of YAP , a candidate oncogene on the chromosome 11q22 ampliconProceedings of the National Academy of Sciences, 2006
- The Hippo Signaling Pathway Coordinately Regulates Cell Proliferation and Apoptosis by Inactivating Yorkie, the Drosophila Homolog of YAPCell, 2005